Skip to main content
    T

    Tango Therapeutics Inc (TNGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $22.11
    -2.06 (-8.52%)

    Market Cap: $4.32B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Tango Therapeutics Inc (TNGX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Tango Therapeutics (TNGX) has a market cap of $4.32B and an enterprise value of $4.23B. Its share count is up 56.74% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 2.01% below the market cap, as cash exceeds debt.

    Market Cap$4.32B
    Enterprise Value$4.23B
    Latest price (Nov 17, 2026)$22.11

    Key Dates

    The next earnings report is expected on Mar 3, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 3, 2027 (expected)
    Last Earnings DateNov 9, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 16.05% in the quarter ended Sep 30, 2026 and grew 26.61% a year over 2 years.

    Shares Outstanding173.93M
    Shares Change (YoY)+56.74%
    Shares Change (QoQ)+16.05%
    Share Count Growth (2Y CAGR)+26.61%

    Price Statistics

    The stock is up 170.62% over 52 weeks and trades 6.11% below its 50-day average.

    Beta (1Y)1.68
    52-Week Change+170.62%
    1-Month Change-6.03%
    3-Month Change-12.26%
    6-Month Change+8.92%
    5-Year Change+76.95%
    Total Return (1Y)+170.62%
    Total Return (3Y CAGR)+42.74%
    Total Return (5Y CAGR)+13.26%
    Return vs SPY (1Y)+164.82%
    Max Drawdown (1Y)-36.57%
    Max Drawdown (3Y)-91.46%
    Sharpe Ratio (1Y)1.08
    Correlation with SPY (1Y)0.24
    50-Day Average$23.55
    200-Day Average$23.01
    52-Week Range$7.83 to $34.39
    RSI (14 Days)45.2
    Average Volume (20 Days)4.15M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 39.45x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio39.45x
    Quick Ratio39.45x
    Debt / Equity0.00x
    Interest Coverage15.12x

    Returns and Efficiency

    Return on equity is -21.22% over the last 12 months, against a 5-year average of -39.02%.

    Return on Equity (ROE)-21.22%
    Return on Assets (ROA)-20.13%
    ROE (5Y Average)-39.02%
    ROA (5Y Average)-25.67%
    ROIC (5Y Average)-30.97%

    Scores

    TNGX has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$479.00K
    Operating Income-$228.53M
    Pretax Income-$208.05M
    Net Income-$208.00M
    Reported EPS (TTM)-$1.37

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 95.16% of the $1.03B in total assets.

    Cash and Equivalents$86.83M
    Total Debt$0
    Net Cash$86.83M
    Net Cash Per Share$0.50
    Working Capital$967.50M
    Shareholder Equity$980.17M
    Book Value Per Share$5.64
    Total Assets$1.03B
    Total Liabilities$53.29M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $321.00K of capital spending, operating cash flow left -$150.41M of free cash flow.

    Operating Cash Flow-$150.09M
    Capital Expenditures$321.00K
    Free Cash Flow-$150.41M
    FCF Per Share-$0.89
    Depreciation and Amortization$1.79M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Revenue grew 35.89% a year over 3 years.

    Revenue Growth (3Y CAGR)+35.89%
    Revenue Growth (5Y CAGR)+52.13%
    Book Value Per Share Growth (2Y CAGR)+6.21%
    Tangible Book Per Share Growth (2Y CAGR)+6.21%

    Revenue and profit by year

    Dividends and Yields

    TNGX does not pay a dividend. Its free cash flow yield is -3.91%.

    FCF Yield-3.91%
    Buyback Yield-25.33%
    Shareholder Yield-25.33%

    Analyst Forecast

    Consensus estimates put revenue growth at -79.52% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-79.52%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About TNGX

    What is TNGX's market cap?

    Tango Therapeutics has a market cap of $4.32B. Its enterprise value, which adds debt and subtracts cash, is $4.23B.

    How many shares of TNGX are outstanding?

    Tango Therapeutics has 173.93M shares outstanding. The count is up 56.74% from a year earlier.

    Does TNGX pay a dividend?

    No. Tango Therapeutics does not pay a dividend.

    How much debt does TNGX have?

    Tango Therapeutics has $0 of total debt and $86.83M of cash and equivalents, a net cash position of $86.83M.